All In Biotech

Drug Trial Radar · NCT03851627

Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Overweight/Obese Men With T2DM or Prediabetes and Hypogonadism

52 Week RCT to Investigate the Effect of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Obese/Overweight Men With T2DM/Prediabetes and Hypogonadism and Subsequent 108 Week Open Label Phase to Investigate Effects on Cardiometabolic Parameters

Last checked: Nov 20, 2026Latest source record: Mar 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Jan 25, 2022

Primary completion

Sep 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Alexandra Kautzky-WillerAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Bayer
First posted
Feb 22, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The epidemics of obesity, MeTSy, T2DM and CVD are increasing worldwide. Non-alcoholic fatty liver disease (NAFLD) is becoming recognized as a condition possibly involved in the pathogenesis of these diseases. The prevailing hypothesis for NAFLD pathogenesis is the 'two-hit' model, with insulin resistance and hyperinsulinemia playing essential roles, which have a plethora of effects on hepatic lipid metabolism and can lead to accumulation of triglycerides in hepatocytes. Accepted treatment for NAFLD is lifestyle modifications. Sex hormones might be relevant in T2DM development and treatment. Low testosterone (T) has deteriorating effects on glucose levels, and aggravates in obesity as aromatization of T is enhanced. T deficiency is related to increases of visceral fat accumulation and associated with development of NAFLD. T replacement might be a successful way in hypogonadism to treat obesity and counteract progression of MEtSy,T2DM or CVD driven by visceral fat accumulation or NAFLD. Primary Objective To investigate the effects on hepatic lipid content reduction of a therapy with Testosterone undecanoate 1000mg compared to placebo given for 52 weeks in patients with type 2 diabetes mellitus and hypogonadism.

Conditions

  • Fatty Liver
  • Overweight/Obesity
  • Prediabetes/Type2 Diabetes Mellitus
  • Hypogonadism, Male

Interventions

  • Testosterone UndecanoateDrug

    1000mg/4ml i.m. initial, after 6 weeks, every 10 weeks thereafter

  • PlaceboDrug

    Placebo Arm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Liver fatTime frame: baseline to week 52, and after 2 years follow up

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Abt. für Endokrinologie & Stoffwechsel, Univ. Klin f. Innere Medizin III

    Vienna, Austria · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.